ArticleCureus2024
Hypertrophic Osteoarthropathy Mimicking Rheumatoid Arthritis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-term efficacy of adalimumab in elderly patients with rheumatoid arthritis and associated risk factors.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic rheumatologic syndromes encompass a range of clinical conditions that mimic primary rheumatic diseases and occur in the context of malignancy. Hypertrophic osteoarthropathy (HOA) is a notable example of such a syndrome, which is frequently associated with intrathoracic malignancies, including primary lung tumors and metastases. This report presents a case of a patient diagnosed with HOA secondary to lung adenocarcinoma, who was admitted with symmetric polyarthritis that resembled elderly-onset rheumatoid arthritis. Anti-cyclic citrullinated peptide (anti-CCP) antibodies are primarily associated with rheumatoid arthritis, but their levels can be falsely elevated in various other conditions. In clinical practice, it's essential to interpret anti-CCP antibody results in conjunction with other clinical findings and laboratory tests to arrive at an accurate diagnosis. This case underscores the importance of considering HOA in the differential diagnosis of inflammatory arthritis, particularly in patients with a known or suspected malignancy, especially in the presence of positive rheumatoid arthritis-specific antibodies. Also, recognition and treatment of the underlying condition can lead to substantial improvements in both rheumatologic and oncologic aspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.